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Abstract
Historically genotypic variation has been detected at the phenotypic level, at the metabolic
level, and at the protein chemistry level. Advances in technology have allowed its direct
visualisation at the level of DNA variation. Nevertheless, there is still an enormous interest
in phenotypic, metabolic and protein property variability, since such variation gives
insights into potential functionally important differences conferred by genetic variation.
High-throughput transcriptomics and proteomics applied to different individuals drawn
from a population has the potential to identify the functional consequences of genetic
variability, in terms of either differences in expression of mRNA or in terms of differences
in the quantities, pI(s) or molecular weight(s) of an expressed protein. Family studies can
deﬁne the genetic component of such variation (segregation analysis) and with the geno-
typing of well-spaced markers can map the causative factors to broad chromosomal regions
(linkage analysis). Association studies in the variant proteins have the greatest power to
conﬁrm the presence of cis-acting genetic variants. The most powerful study designs may
combine elements of both family and association studies applied to proteomic and
transcriptomic analyses. Such studies may provide appreciable advances in our under-
standing of the genetic aetiology of complex disorders. Copyright # 2002 John Wiley &
Sons, Ltd.
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Background
For the past two decades much attention has been
focused on detecting the genetic variation involved
in monogenic disorders of major effect, such as
cystic ﬁbrosis [1,2] and retinitis pigmentosa [3].
These have been mapped to broad chromosomal
regions by following the co-segregation in families
of the disease with a limited panel of polymorphic
markers located at intervals along human chromo-
somes (linkage analysis). For complex disorders
such as cardiovascular and psychiatric disease there
is a strong heritable component, however, this
results from the accumulated small effects of
many functional polymorphisms. Linkage analysis
is not so powerful in these cases, since there is only
a small increase in the marker co-segregation of
a given polymorphism with the disease [4]. Even
association studies may have limited power if the
number of patients studied with a homogeneous
phenotype is restricted. Thus, the scientiﬁc literature
abounds with conﬂicting reports regarding the
signiﬁcance of associations between particular gene-
tic variants and disease [5,6,7]. Association studies
have the greater drawback that, until larger sample
sizes and cheaper genotyping can justify genome-
wide scans [4], they generally start with candidate
loci. An absence of association of a given variant
does not exclude that protein from a role in the
disease (since many polymorphisms have no phy-
siological signiﬁcance). Conversely, the presence of
a weak association does not prove that the protein
is critical. Many of the risk factors associated with
cardiovascular disease identiﬁed through associa-
tion studies confer low risks (of the order of a
10% increase in risk) when meta-analysis of many
studies is performed [8,9], which may largely explain
the inability of many studies to detect signiﬁcant
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eral population (whose study has changed the
understanding of a disease process) have in the
past been frequently initially detected through
biochemical, rather than genetic approaches (eg.,
the coagulation Factor V Leiden variant [10]). The
challenge going forward for complex diseases is to
carry out genetic studies that provide novel and
interesting insights into the biological processes
rather than merely conﬁrming what is known of
the disease process from other studies. Since the
links between the genotypic variants and the disease
outcome are weak, the means to improve under-
standing is to collect information on the inter-
mediate RNA, protein and metabolic mediators
of risk between genotype and disease. Genotypic
data has one crucial feature which makes it valu-
able in constructing causal models in complex disease:
unlike the RNA, protein and metabolic phenotypes,
the genotype is generally not modiﬁed by the
disease process itself. Such causal models require
genotypic information, disease status information,
and the intermediate biomolecular information. The
development of high-throughput technologies for
genotyping, for studying many RNA species simul-
taneously (transcriptomics) and for studying many
protein species simultaneously (proteomics) offers a
powerful approach for the genetic dissection of
complex disorders.
Genetically determined variability in
mRNA expression level
Studies of genetic variation in mRNA levels of
genes are currently mainly limited to analyses of
genetic variants in the regulatory regions of genes.
The impact of such regulatory variants on the
expression of the gene can be assessed by generat-
ing gene constructs and introducing them into
experimental cellular systems. There is a growing
literature of such information but no centralised
database of such experimental ﬁndings, detailing
the tissue origin of the cell line used and the relative
levels of expression of the alternative variants. The
physiological relevance of mRNA expression differ-
ences in cell systems to in vivo expression is usually
not explored. However, it is also feasible to directly
investigate mRNA level in relation to genotype. For
example, the level of Angiotensin-1 converting
enzyme mRNA was measured in kidney biopsies
from 50 patients and correlated with genotypic
differences in the well-studied insertion-deletion
polymorphism in this gene [11]. Ex vivo mRNA
analysis in cells cultured from a number of indivi-
duals provides another way to compare inter-
individual variation in mRNA level with genotype
[12]. This provides greater control of the conditions
for handling and processing the RNA, although it is
one step away from the true physiological context.
cDNA microarrays have been used in comparing
the expression pattern in patients with different
disease-causing genotypes, for example in the com-
parison of cancer gene expression proﬁles between
BRCA1 and BRCA2 carriers [13]. Such a compar-
ison is looking at the downstream (trans) effect of a
very large genotypic difference on gene expression.
The challenge will be to identify less striking, but
biologically important, associations between many
possible genotypic variants and changes in mRNA
expression, both in cis and in trans [14]. To date,
microarray analyses have been most useful in
cancer studies, where the very marked alterations
in the co-ordinated expression of groups of genes lie
well outside the margins of experimental error
found with current microarray analyses.
Genetically determined variability at the
protein level
Proteomics is the surveying of a large number of
proteins at once. Currently, the main technology is
separation by two-dimensional gel electrophoresis,
whose analytical capabilities have been accelerated
in the last few years by rapid protein identiﬁca-
tion using mass spectrometry. This is likely to be
routinely augmented in the future by more sensi-
tive technologies. Here we give examples of some
of the genetically determined factors identiﬁed in
two-dimensional gels.
Detection of genetically determined protein
variation
Genetically determined variation may potentially be
observed by whatever means proteins are studied.
Anderson and Anderson [15] silver stained two-
dimensional gels to observe a number of poly-
morphisms among the abundant proteins detectable
on the gel. More speciﬁc analyses restrict the num-
ber of proteins observed, for example by immuno-
blotting against a single protein [16], or group of
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transferases [18].
Classes of genetic variants
Genetic variants that have been analysed using 2-D
gels include: (a) common polymorphisms, observed
as protein variations between individuals drawn
from a species, eg. in human serum [15], or in maize
[19], (b) rare disease mutations [16], (c) somatic
mutations observed in cancer cells [18], or (d) novel
variants induced experimentally by mutagenesis [20].
Nature of protein variability detectable on 2D
gel
Variation may be in the quantity [19,20], size, or
isoelectric point (pI) of the protein, or it may be
whether or not the protein forms large molecular
weight, higher-order protein complexes under con-
trolled conditions of protein preparation [16].
Action of genetic polymorphism on protein
molecular phenotype
Genetic variants may act in cis (the genetic vari-
ation affecting the protein’s appearance on the gel
lies within the gene for the protein) or in trans (the
genetic variation inﬂuencing the protein lies within
another gene which inﬂuences the level of expres-
sion, or the post-translational modiﬁcation, of the
protein [19]). Linkage analysis can reveal whether
the underlying variation maps to the chromosomal
region of the gene that encodes the variant protein
(cis), or whether it lies outside this region (trans)
[19].
Family/pedigree and association studies
Segregation analysis of molecular phenotypes
Historically, genetic analyses of complex diseases in
humans have often involved a segregation analysis
of the disease condition to determine if its pattern
of inheritance in families follows dominant, reces-
sive, or polygenic models, or some mixture of the
above, and to estimate the likelihood of disease
given a particular genetic make-up (penetrance) as
well as the likely frequency of the alleles in the
population [21]. A simpler approach is to calculate
the relative risk to a sibling of having the pheno-
type, compared to the risk of an unrelated control.
However, this simpler method ignores whether
the molecular variant is behaving in a recessive,
dominant or dose-dependent manner, and may
therefore be less powerful. Segregation analysis in
pedigrees or families permits an estimation of the
heritability of the molecular phenotype [14].
Linkage analysis of molecular phenotypes
Linkage analysis [22] of a molecular phenotype
offers the potential to determine if the factor
underlying the variation lies within the chromoso-
mal region of the gene that encodes the gene
product, or outside it.
Association studies
Association studies simply ask: in a group of unre-
lated individuals, is a certain genotype more fre-
quent with a certain phenotype. The phenotype may
be a comparison of cases with controls (such as
persons with a protein variant of a particular mass
and pI compared to controls who lack this variant),
or alternatively a study of a quantitative variable
(such as protein or RNA level) within a group.
Study design and power
Segregation, linkage and association analyses pro-
vide the three basic tools whereby the links bet-
ween genotype and a molecular phenotype can be
explored. Each may be of use on its own, since a
protein variant which segregates strongly in a
Mendelian fashion may be a marker for important
disease processes measurable in the clinical pheno-
type. While a strong Mendelian pattern of inheri-
tance may be more usually consistent with a cis
effect within the protein, segregation analysis alone
cannot determine if the genetic variability lies
within the gene encoding the protein. Linkage
analysis will determine the broad chromosomal
location of the genetic variant underlying a mole-
cular phenotype. Linkage analysis has the advan-
tage that the genome-wide scan of well-spaced,
informative markers, once performed, can be used
to potentially map all the molecular variants, which
may each be analysed as quantitative trait loci [14]
or subjected to combined segregation and linkage
analyses [23]. Linkage analysis may be of particular
interest in the detection of protein–protein inter-
actions, since trans-acting genetic factors modify-
ing a protein’s pI, molecular weight or level may
be broadly mapped to a chromosomal region.
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linkage analysis to reasonably narrow chromosomal
regions with smaller numbers of candidate genes,
quite a large panel of families may be required.
Association studies are quicker and easier, but they
may be best carried out after an initial segregation
analysis, to prevent extensive negative studies of
variations that have little or no strong genetic basis.
Association studies can directly assess whether
known polymorphisms within the variant protein
can account for that polymorphism. Direct obser-
vation of a single causal variant is always more
powerful than linkage analysis. Linkage analysis is
likely to be more powerful than whole-genome
association studies for molecular variants with high
heritability [4]. Thus, association studies may be the
approach of choice for cis effects, while linkage
analysis is appropriate for detecting any possible
trans effects. The best study design may combine all
three approaches.
Further integration of genetic,
transcriptomic and proteomic data
Study design and subsequent interpretation may
be conditioned on a priori biological information.
For example, polymorphisms analysed may be initi-
ally restricted to those which are more likely to be
of functional importance [24]. Trans-acting changes
may affect large numbers of genes (eg., genetic
variation in a critical signalling pathway could
inﬂuence a co-ordinated increase in the levels of a
group of genes). Interpretation of biological clus-
ters of changes may rely on a priori classiﬁcation
of gene functions based on general classiﬁcations
(eg., see www.geneontology.org), or on other means
of clustering genes [25] (co-occurrence in species;
co-expression in tissues; experimentally observed
protein–protein interactions; clusters of homolo-
gous proteins; automated interpretation of data-
bases of scientiﬁc literature). This broader level of
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Figure 1. Representation of data ﬂow in a study of human disease integrating genotypic data with proteomic and expression
analysis. Block arrows represent the major ﬂow of data, thin arrows indicate the possible linkages between the analysis
database and the underlying raw data
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questions of relating genotypic variation to other
molecular variation, but will need to be addressed.
Integration of the clinical data from each patient in
terms of genes, proteins and messages itself repre-
sents a reasonably complex task depending on how
much the ﬁnal analytical database takes forward
from the raw experimental data, and how much it
relies on summaries across experiments and data-
base searches (Figure 1).
Conclusions
Integration of genotypic, proteomic and transcrip-
tomic data is technically feasible. Over the past
three decades numerous analyses of genetic varia-
bility underlying mRNA and protein variation,
usually restricted to a relatively limited number of
gene products, have accumulated. Whilst the geno-
typing component is relatively straightforward, the
challenge is to scale such studies up for high-
throughput analyses that can measure the protein
and mRNA products at the required sensitivity.
Such integrated studies with well-measured molecu-
lar and clinical phenotypes in humans have the
potential to transform our understanding of the
genetic basis of complex disorders. However, initial
advances may come via the application of these
methods to transgenic and model organisms [14,26],
where well designed experimental crosses between
diverged strains appear to be highly informative in
detecting protein expression differences with a
genetic aetiology [19].
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